ライフサイエンスコーパス: golimumab

1 umab and the TNF-inhibitors certolizumab and golimumab).

2 Alternatives to infliximab are ADA and golimumab.

3 benefit was maintained through week 52 with golimumab.

4 ylosing spondylitis from phase III trials of golimumab.

5 nders in the induction study received 100 mg golimumab.

6 ated with a lower incidence of antibodies to golimumab.

7 ebo (n = 113), golimumab 50 mg (n = 146), or golimumab 100 mg (n = 146) every 4 weeks through week 20

8 limumab 50 mg, and 45% of patients receiving golimumab 100 mg achieved an ACR20 response (the primary

9 mg, golimumab 50 mg increased to 100 mg, and golimumab 100 mg continued at 100 mg.

10 ve subcutaneous placebo, golimumab 50 mg, or golimumab 100 mg every 4 weeks through week 20.

11 olimumab 50 mg group and 58% of those in the golimumab 100 mg group had at least 75% improvement in t

12 p 2), golimumab 50 mg plus MTX (group 3), or golimumab 100 mg plus MTX (group 4).

13 p 2), golimumab 50 mg plus MTX (group 3), or golimumab 100 mg plus MTX (group 4).

14 igned to receive placebo plus MTX (group 1), golimumab 100 mg plus placebo (group 2), golimumab 50 mg

15 mized to receive placebo plus MTX (group 1), golimumab 100 mg plus placebo (group 2), golimumab 50 mg

16 = .004 and P = .002, respectively) or 50 mg golimumab (23.2% and 41.7%, respectively).

17 es were highest among those who had received golimumab 4 mg/kg plus MTX (70% and 48%, respectively).

18 week 54 in 47.0% of patients receiving 50 mg golimumab, 49.7% of patients receiving 100 mg golimumab,

19 ubcutaneous injections of placebo (n = 113), golimumab 50 mg (n = 146), or golimumab 100 mg (n = 146)

20 HS from baseline to week 24 for the combined golimumab 50 mg and 100 mg group (-0.09) and the golimum

21 ndomized: 113 to placebo and 146 each to the golimumab 50 mg and 100 mg groups.

22 enter the early escape phase crossed over to golimumab 50 mg at week 24.

23 mumab 50 mg and 100 mg group (-0.09) and the golimumab 50 mg group (-0.16) were significantly differe

24 y psoriasis at baseline, 40% of those in the golimumab 50 mg group and 58% of those in the golimumab

25 , with placebo crossover to golimumab 50 mg, golimumab 50 mg increased to 100 mg, and golimumab 100 m

26 1), golimumab 100 mg plus placebo (group 2), golimumab 50 mg plus MTX (group 3), or golimumab 100 mg

27 1), golimumab 100 mg plus placebo (group 2), golimumab 50 mg plus MTX (group 3), or golimumab 100 mg

28 ceiving golimumab, 51% of patients receiving golimumab 50 mg, and 45% of patients receiving golimumab

29 arly escape phase, with placebo crossover to golimumab 50 mg, golimumab 50 mg increased to 100 mg, an

30 ly assigned to receive subcutaneous placebo, golimumab 50 mg, or golimumab 100 mg every 4 weeks throu

31 Golimumab (50 mg or 100 mg) maintained clinical response

32 At week 14, 48% of all patients receiving golimumab, 51% of patients receiving golimumab 50 mg, an

33 Subcutaneous golimumab, a fully human monoclonal antibody to tumor ne

34 Golimumab, administered subcutaneously every 4 weeks, ha

35 plus MTX is better than, and the efficacy of golimumab alone is similar to, the efficacy of MTX alone

36 ents who responded to induction therapy with golimumab and had moderate-to-severe active ulcerative c

37 failure, all in patients who received 100 mg golimumab) and 4 developed active tuberculosis.

38 olimumab, 49.7% of patients receiving 100 mg golimumab, and 31.2% of patients receiving placebo (P =

39 b, infliximab, methotrexate, apremilast, and golimumab are recommended.

40 at new anti-TNF agents, adalimumab (ADA) and golimumab, are effective in induction of remission and m

41 placebo plus MTX or intravenous infusions of golimumab at a dose of 2 mg/kg or 4 mg/kg, with or witho

42 Treatment with golimumab at doses of 50 mg and 100 mg significantly imp

43 Methotrexate (MTX)-naive patients (in the Golimumab Before Employing Methotrexate as theFirst-Line

44 ly include mAbs (infliximab, adalimumab, and golimumab), either chimeric or human in sequence, a PEGy

45 tions of placebo plus MTX or 50 mg or 100 mg golimumab every 2 or 4 weeks plus MTX through week 48.

46 9% of patients in the group receiving 100 mg golimumab every 2 weeks achieved an ACR20 response (P<0.

47 given placebo or injections of 50 or 100 mg golimumab every 4 weeks through week 52.

48 se, and the PsA-modified MASES index in each golimumab group compared with placebo.

49 e in the primary end point when the combined golimumab groups and at least 1 of the individual dose g

50 e reported in 9% of patients in the combined golimumab groups and in 6% of patients in the placebo gr

51 rative colitis; patients who received 100 mg golimumab had clinical remission and mucosal healing at

52 om phase 3 clinical trials of infliximab and golimumab, high pretreatment expression of OSM is strong

53 s with active RA despite MTX therapy (in the Golimumab in Active Rheumatoid Arthritis Despite Methotr

54 Golimumab in combination with MTX inhibited radiographic

55 reported for other TNFalpha antagonists and golimumab in other approved indications.

56 Among all patients given golimumab in the study, 3 died (from sepsis, tuberculosi

57 the long-term efficacy and safety of ADA and golimumab in ulcerative colitis.

58 spite conventional therapy, who responded to golimumab induction therapy.

59 double-blind trial of patients who completed golimumab induction trials (Program of Ulcerative Coliti

60 owed that all biological agents (adalimumab, golimumab, infliximab, and vedolizumab) resulted in more

61 Treatment of PsA with golimumab inhibited structural damage progression and de

62 n ACR50 response between the group receiving golimumab monotherapy and the group receiving placebo pl

63 ents who responded to induction therapy with golimumab (n = 464) were assigned randomly to groups giv

64 ding an adequate assessment of the effect of golimumab on radiographic progression in this study.

65 Subcutaneous injections of golimumab or placebo were administered every 4 weeks.

66 Golimumab orplacebo was administered subcutaneously ever

67 However, intravenously administered golimumab plus MTX appears to have benefit in the longer

68 observed in 21% of the patients treated with golimumab plus MTX compared with 13% of the patients tre

69 The combination of golimumab plus MTX demonstrated a significantly better r

70 ixty-one percent of patients in the combined golimumab plus MTX dose groups achieved an ACR20 respons

71 Golimumab plus MTX effectively reduces the signs and sym

72 24, significantly more patients treated with golimumab plus MTX had achieved an ACR50 response.

73 y measures demonstrated that the efficacy of golimumab plus MTX is better than, and the efficacy of g

74 ong patients given placebo, 50 mg, or 100 mg golimumab, respectively; percentages of serious infectio

75 derwent both IGRA and TST screening prior to golimumab treatment.

76 Golimumab was generally well tolerated.

77 r percentage of patients who received 100 mg golimumab were in clinical remission and had mucosal hea

78 ere infections (48% of patients treated with golimumab with or without MTX and 41% of patients receiv